asco 2022: efficacy of cabozantinib atezolizumab to treat urothelial carcinoma
Published 2 years ago • 146 plays • Length 2:31Download video MP4
Download video MP3
Similar videos
-
3:34
abacus trial: preoperative atezolizumab in urothelial carcinoma
-
8:27
urothelial carcinoma: ev-301 update from asco 2022
-
4:43
asco: cabozantinib and atezolizumab in urothelial cancer
-
5:12
safety and efficacy of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma
-
2:30
abacus updates: positive results for preoperative atezolizumab in bladder cancer
-
7:08
final analysis of the atlantis cabozantinib comparison
-
1:34
phase 2 trial of cv301 vaccine plus atezolizumab in advanced urothelial carcinoma
-
3:23
fort-2: rogaratinib and atezolizumab in urothelial cancer
-
2:18
final os results of imvigor130: 1l atezolizumab /- chemotherapy in metastatic urothelial carcinoma
-
1:19
dr. agarwal on the safety of cabozantinib/atezolizumab in mcrpc
-
6:49
fda approval of atezolizumab for advanced bladder cancer
-
0:39
bladder cancer highlights at asco 2022
-
1:16
dr. ezra cohen discusses the cabozantinib dose size and tolerability
-
8:50
asco genitourinary cancer updates: 2023 review and renew lake tahoe
-
1:10
highlights in bladder cancer from asco 2022
-
7:05
the fda approval of atezolizumab in bladder cancer
-
31:06
bladder cancer | 2022 oneoncology conference
-
5:03
atezolizumab with ebrt for bladder preservation in mibc
-
0:51
dr. pal on the rationale for adding cabozantinib to atezolizumab in prostate cancer